- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Can-Fite Obtains Patent in Korea for Treatment of Psoriasis
Can-Fite BioPharma announced it obtained a patent from the Korean Intellectual Property Office for the Company’s lead drug candidate Piclidenoson in its psoriasis indication.
Can-Fite BioPharma (NYSE:CANF) announced it obtained a patent from the Korean Intellectual Property Office for the Company’s lead drug candidate Piclidenoson (CF101) in its psoriasis indication.
As quoted in the press release:
Can-Fite has two distribution agreements in Korea including one with Kwang Dong Pharmaceutical for Piclidenoson in the treatment of rheumatoid arthritis and another with Chong Kun Dang for Namodenoson in the treatment of liver cancer.
“Korea is an important market for us, as evidenced by the two distribution agreements we already have there. This patent may increase the value of a potential distribution deal in Korea for Piclidenoson in the treatment of psoriasis,” stated Can-Fite CEO Dr. Pnina Fishman. “We believe Piclidenoson is a strong candidate for the treatment of moderate to severe psoriasis due to its excellent safety profile for long-term use and its favorable comparison with Otezla, the leading oral therapy currently on the market.”
Click here to read the full press release.
Source: www.businesswire.com
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.